Dorelsa Buccilli
Overview
Explore the profile of Dorelsa Buccilli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Civita M, Torchia A, Santini D, Marinelli D, Magro V, Cerro M, et al.
Curr Oncol
. 2024 Aug;
31(8):4713-4727.
PMID: 39195335
Introduction: Platinum-based chemotherapy represents the standard of care (SoC) for the first-line treatment of advanced urothelial carcinoma (mUC). The benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy was...
2.
Santamaria F, Roberto M, Buccilli D, Di Civita M, Giancontieri P, Maltese G, et al.
Crit Rev Oncol Hematol
. 2024 Jun;
200:104405.
PMID: 38838928
In the last two-decades, innovative drugs have revolutionized cancer treatments, demonstrating a significant improvement in overall survival. These drugs may present several pharmacokinetics interactions with non-oncological drugs, and vice versa,...
3.
Magri V, Marino L, De Renzi G, De Meo M, Salvatori F, Buccilli D, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397990
Early detection of disease progression is a crucial issue in the management of cancer patients, especially in metastatic settings. Currently, treatment selection mostly relies on criteria based on radiologic evaluations...
4.
Roberto M, Panebianco M, Aschelter A, Buccilli D, Cantisani C, Caponnetto S, et al.
Front Oncol
. 2023 Jan;
12:1026978.
PMID: 36713496
The new landscape of treatments for metastatic clear cell renal carcinoma (mRCC) is constantly expanding, but it is associated with the emergence of novel toxicities, adding to up to those...
5.
Barchetti G, Simone G, Ceravolo I, Salvo V, Campa R, Del Giudice F, et al.
Eur Radiol
. 2019 Mar;
29(10):5498-5506.
PMID: 30887202
Objectives: To evaluate accuracy and inter-observer variability using Vesical Imaging-Reporting and Data System (VI-RADS) for discrimination between non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Methods: Between September...